ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2016

Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel.

Oscar Arrieta et al.PubMed ↗Publisher ↗

No numbers read from the abstract.